arrow
M

Marcel Nijland

University of Groningen
H指数:24
被引数:2,343

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab consolidation in patients with double and triple hit high-grade B-cell lymphoma in complete metabolic remission after DA-EPOCH-R

Nivolumab巩固治疗在完成DA-EPOCH-R方案后达到完全代谢缓解的双打击和三打击高危B细胞淋巴瘤患者中的应用

2026-10-300
OA
Multiple myeloma in the Netherlands: 35-year trends in incidence and survival

荷兰多发性骨髓瘤:35年发病率和生存趋势

Leukemia
IF13.4
2026-10-220
OAAI
Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA

利用游离DNA进行移植后淋巴增生性疾病的分子分型和疾病追踪

2026-08-280
OA
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial

Epcoritamab联合利妥昔单抗和来那度胺作为滤泡性淋巴瘤的一线治疗(EPCORE NHL-2):一项开放标签、多中心、1/2b期临床试验

2026-08-270
OA
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

使用epcoritamab联合 bendamustine和rituximab的一线治疗在滤泡性淋巴瘤患者中诱导了超过3年的持续缓解

2026-08-050
OAAI
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Epcoritamab、lenalidomide和rituximab与lenalidomide和rituximab治疗复发或难治性滤泡性淋巴瘤的比较(EPCORE FL-1):一项全球性、开放标签、随机、III期临床试验

2025-12-070
OAAI
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

固定疗程的Epcoritamab联合R2方案可改善复发或难治性滤泡性淋巴瘤患者的预后。

Blood
IF23.1
2025-09-100
OAAI
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment

骨内弥漫性大B细胞淋巴瘤中,免疫富集肿瘤微环境与更优生存率相关。

2025-04-290
OA
Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP

Atezolizumab巩固治疗在完成R-CHOP治疗后达到完全缓解的高危弥漫性大B细胞淋巴瘤患者中的应用

2025-04-210
OA
Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics

经典霍奇金淋巴瘤患者细胞外DNA的分子特征分析鉴定了潜在的预后聚类,并与疾病动态相对应

2025-04-080
OA
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
2024-12-010
PRE
Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse

与第二次高剂量疗法及自体干细胞移植相结合的巩固治疗,与处于首次复发的多发性骨髓瘤患者的总体生存率改善相关。

2024-12-010
OAAI
Immunosuppressed Tumor Microenvironment in MYC-Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

MYC重排的高级别B细胞淋巴瘤与未特别指明的弥漫性大B细胞淋巴瘤相比的免疫抑制性肿瘤微环境

BLOOD
IF23.1
2024-11-050
PRE